Robotic Lung Biopsy Market Poised for Major Growth from 2025 to 2035
The global robotic lung biopsy market is undergoing a profound transformation, redefining how lung cancer and pulmonary disorders are diagnosed. Estimated at USD 490.1 billion in 2025, the market is forecast to more than double, reaching USD 1225.7 billion by 2035, advancing at a robust CAGR of 9.6%. This exceptional growth underscores the critical role robotic technologies are playing in healthcare, particularly in improving accuracy, efficiency, and patient comfort.
Rising Global Burden of Lung Cancer Driving Demand
Lung cancer remains one of the most significant healthcare challenges worldwide, and early detection is often the key to successful treatment. Traditional biopsy methods, while valuable, have faced challenges with precision, patient discomfort, and risk of complications. Robotic lung biopsy systems are emerging as the solution to these barriers, providing physicians with advanced tools that combine imaging, navigation, and robotic control for minimally invasive, highly accurate diagnostics.
The rising incidence of chronic obstructive pulmonary disease (COPD) and other respiratory conditions adds further urgency to adopting these technologies. Hospitals and research institutes are investing heavily to integrate robotic lung biopsies into their clinical pathways, reducing repeat procedures and improving outcomes for patients.
Full Market Report available for delivery. For purchase or customization, please request here: https://www.futuremarketinsights.com/reports/sample/rep-gb-17225
Systems Leading the Product Segment
Within product and services, the system segment is expected to command 54.2% of the market in 2025. These systems provide a unified solution, combining navigation, robotic arms, and imaging integration to streamline the procedure. Their efficiency and ability to deliver reproducible results are driving demand across major healthcare facilities.
Technological advancements are adding further momentum, with manufacturers integrating artificial intelligence and real-time imaging for improved accuracy. Hospitals that adopt these advanced systems not only improve their patient care standards but also gain a competitive edge in offering cutting-edge medical services.
Navigation Technologies Becoming the Heart of Innovation
The navigation technology segment, particularly electromagnetic and optical navigation, will hold 62.7% market share in 2025. These technologies provide physicians with real-time guidance, enabling them to access even the smallest and most challenging lung nodules. By increasing localization accuracy, they reduce procedural risks and enhance confidence in diagnosis.
Fiber optic realshape navigation is also expected to gain traction in the coming decade, offering 3D visualization of full-shape devices inside the body. This groundbreaking innovation allows unprecedented precision during biopsy procedures, marking the future of robotic diagnostics.
Hospitals Emerging as the Leading End Users
Hospitals are forecast to capture 48.5% of the market by 2025, solidifying their role as the primary end users of robotic lung biopsy systems. Their access to advanced infrastructure, trained professionals, and reimbursement frameworks makes hospitals the natural hub for these technologies.
As patient inflows rise and the need for quick, accurate diagnostics intensifies, hospitals are increasingly investing in robotic systems. Their commitment to reducing diagnostic turnaround time while ensuring patient safety is driving this trend. By 2035, hospitals are expected to remain the cornerstone of the market, continuing to adopt advanced robotic systems at scale.
A Decade of Change: 2020 to 2035
From 2020 to 2025, the robotic lung biopsy market was still in its early adoption phase, recording a CAGR of 11.2%. High costs, limited access, and cautious adoption slowed down the growth initially. However, by 2025, adoption began accelerating, driven by successful deployments like Intuitive Surgical’s Ion endoluminal platform, with more than 300 installations worldwide.
Looking forward, 2025 to 2035 is expected to be the decade of mainstream adoption. With costs gradually decreasing, more hospitals will integrate robotic biopsy systems into their workflows. The market is forecast to maintain steady expansion at 9.6% CAGR, reshaping diagnostic protocols worldwide.
Regional Insights
In the United States, the market is set to reach USD 1225.7 million by 2035, growing at a CAGR of 10.8%. The country benefits from a strong robotics ecosystem, early adoption of AI in healthcare, and a high incidence of lung cancer. With the elderly population at greater risk of pulmonary conditions, robotic lung biopsies are rapidly gaining acceptance as safer alternatives.
The United Kingdom is also witnessing strong adoption, projected to grow at 8.2% CAGR. Government support through the NHS for robotic technologies and rising awareness among patients are fueling the market.
China and Japan are presenting exciting opportunities, with China expected to grow at 7.7% CAGR and Japan at 9.7%. China’s healthcare modernization, coupled with rising disposable incomes, makes it a fertile market for robotic solutions, while Japan’s reputation for embracing medical innovation positions it as a leader in advanced diagnostics.
South Korea, though smaller in size, is progressing steadily with a 5.5% CAGR. Its robust healthcare infrastructure and openness to adopting cutting-edge medical technologies make it a promising player in Asia’s robotics adoption story.
Innovation in Instruments and Accessories
While systems dominate the market, instruments and accessories are projected to grow even faster, at a CAGR of 10.9% through 2035. Robotic instruments provide surgeons with enhanced dexterity, precision, and control, enabling them to navigate delicate tissue structures safely. Ergonomic designs also reduce surgeon fatigue, supporting longer and more complex procedures.
These instruments are critical for expanding the usability of robotic systems, and their growing demand highlights the importance of accessory innovation in sustaining overall market growth.
Request Market Research Draft Report: https://www.futuremarketinsights.com/reports/brochure/rep-gb-17225
Competitive Landscape
The robotic lung biopsy market is defined by the interplay of established medical giants and innovative newcomers. Companies like Ethicon, Inc. (Johnson & Johnson) and Intuitive Surgical dominate the field with robust research and global distribution. Their investments in AI integration, imaging capabilities, and ergonomic designs are setting benchmarks for the industry.
However, emerging players and regional manufacturers are introducing niche technologies and cost-effective solutions, broadening access in developing economies. Collaborations, strategic partnerships, and acquisitions are common as companies seek to expand their portfolios and strengthen their presence in both mature and emerging markets.
Recent milestones include Lee Health’s introduction of the Intuitive Ion robotic bronchoscopy platform in 2025, MountainView Hospital’s launch of a new minimally invasive robotic biopsy procedure in 2024, and the Harron Lung Center’s innovative integration of cone-beam CT with robotic bronchoscopy for enhanced pulmonary nodule diagnosis.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: [email protected]



